A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy (NCT06779773)
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
🩺 Plain-English Summary (8th-Grade Level)
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.
Who can join: Review the eligibility criteria below.
Location: Phoenix Retina Clinical Trials, LLC — Phoenix, Arizona
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (65 Sites)
Showing the first 25 of 65 sites.
- Phoenix Retina Clinical Trials, LLC — Phoenix, Arizona
- Retinal Consultants of AZ — Phoenix, Arizona
- Retina Macula Institute of Arizona — Scottsdale, Arizona
- The Retina Partners — Encino, California
- Harvard Eye Associates — Laguna Hills, California
- University of California Irvine Medical Center — Orange, California
- Retina Consultants of Southern CA — Redlands, California
- Retinal Consultants Medical Group Inc — Sacramento, California
- Retina Macula Institute — Torrance, California
- Rocky Mountain Lions Eye Institute — Aurora, Colorado
- Retina Consultants of Southern Colorado — Colorado Springs, Colorado
- Colorado Retina Associates, PLLC — Lakewood, Colorado
- Coastal Eye Surgeons — Greenwich, Connecticut
- Florida Eye Clinic — Altamonte Springs, Florida
- Advanced Retina Institute — Bonita Springs, Florida
- University of Miami — Coral Gables, Florida
- Retina Care Specialists — Palm Beach Gardens, Florida
- Eye Physicians of Pinellas PA dba Eye Institute of West Florida — Tampa, Florida
- Retina Specialists of Tampa — Wesley Chapel, Florida
- Southeast Retina Center, P.C. — Augusta, Georgia
- University Retina and Macula Associates, P.C. — Oak Forest, Illinois
- Illinois Retina Associates — Oak Park, Illinois
- Illinois Eye Center — Peoria, Illinois
- Wolfe Eye Clinic — West Des Moines, Iowa
- Cumberland Valley Retina Consultants,P.C. — Hagerstown, Maryland
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Geographic Atrophy
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) — Scottsdale, Arizona
- A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Bakersfield, California
- Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy — Phoenix, Arizona
- A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy — Gilbert, Arizona
- Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy — Phoenix, Arizona
- A Study in Adults With Geographic Atrophy — Bakersfield, California
Explore by condition: All Geographic Atrophy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.